You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

humanized anti-CD20 veltuzumab (IMMU-106) administered subcutaneously

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NHL, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell Trial in United States (veltuzumab)

Completed
  • NHL
  • +17 more
  • veltuzumab
  • Savannah, Georgia
  • +4 more
Aug 12, 2021

Purpura, Thrombocytopenic, Idiopathic, Autoimmune Thrombocytopenic Purpura, Purpura, Thrombocytopenic, Autoimmune Trial in

Terminated
  • Purpura, Thrombocytopenic, Idiopathic
  • +2 more
  • veltuzumab
  • Los Angeles, California
  • +7 more
Aug 12, 2021

Non Hodgkin's Lymphoma, NHL, Aggressive NHL Trial in United States (Veltuzumab and 90Y-Epratuzumab Tetraxetan, 90Y-epratuzumab

Withdrawn
  • Non Hodgkin's Lymphoma
  • +3 more
  • Veltuzumab and 90Y-Epratuzumab Tetraxetan
  • +2 more
  • Newark, Delaware
  • +6 more
Aug 12, 2021

Non-Hodgkin's Lymphoma, Lymphoma, Diffuse, Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic Trial in Lille, Lyon, Leicester

Completed
  • Non-Hodgkin's Lymphoma
  • +2 more
  • Lille, Cedex, France
  • +2 more
Aug 12, 2021

Non-Hodgkin's Lymphoma Trial in New York, Philadelphia, Houston (hA20-humanized anti-CD20 antibody)

Completed
  • Non-Hodgkin's Lymphoma
  • hA20-humanized anti-CD20 antibody
  • New York, New York
  • +2 more
Aug 12, 2021

Chronic Lymphocytic Leukemia, Richter's Transformation Trial in Boston (Glofitamab, Obinutuzumab, Polatuzumab Vedotin)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Richter's Transformation
  • Boston, Massachusetts
  • +1 more
Sep 12, 2023

Primary Membranous Nephropathy Trial in Beijing (B007)

Not yet recruiting
  • Primary Membranous Nephropathy
  • Beijing, China
    Peking university first hospital
Dec 20, 2022

B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory Trial in China (Orelabrutinib, Recombinant humanized mAb MIL62 injection)

Active, not recruiting
  • B-cell Lymphoma Recurrent
  • B-cell Lymphoma Refractory
  • Orelabrutinib
  • Recombinant humanized monoclonal antibody MIL62 injection
  • Bengbu, Anhui, China
  • +9 more
Nov 11, 2022

Metastatic Breast Cancer Trial in China, Korea, Republic of, Taiwan (sacituzumab govitecan (IMMU-132), Eribulin Mesylate

Recruiting
  • Metastatic Breast Cancer
  • sacituzumab govitecan (IMMU-132)
  • +4 more
  • Beijing, China
  • +43 more
Apr 19, 2022

Glioblastoma Multiforme, Glioblastoma, Adult, Glioma of Brain Trial in Geneva (IMA950/Poly-ICLC, IMA950/Poly-ICLC and

Active, not recruiting
  • Glioblastoma Multiforme
  • +3 more
  • Geneva, Switzerland
    University Hospitals of Geneva
Dec 23, 2022

Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia Trial in Australia,

Recruiting
  • Follicular Lymphoma
  • +7 more
  • Louisville, Kentucky
  • +4 more
Mar 11, 2022

Multiple Sclerosis Trial (Ocrelizumab Injection [Ocrevus])

Not yet recruiting
  • Multiple Sclerosis
  • Ocrelizumab Injection [Ocrevus]
  • (no location specified)
Aug 22, 2023

Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic Trial in West Hollywood

Completed
  • Lupus Erythematosus, Cutaneous
  • +4 more
  • West Hollywood, California
    Cedars Sinai Medical Center-Wallace Rheumatic Study Center
Aug 12, 2021

CD20 Positive B Cell Non-Hodgkin's Lymphoma Trial in Guangzhou, Tianjin (B001)

Completed
  • CD20 Positive B Cell Non-Hodgkin's Lymphoma
  • B001
  • Guangzhou, Guangdong, China
  • +1 more
Nov 11, 2021

Salivary Gland Cancer Trial (vedicitumomab (Edisil, RC48), vedicitumomab in combination with pyrrolizidine, RC48 in combination

Not yet recruiting
  • Salivary Gland Cancer
  • vedicitumomab (Edisil, RC48）
  • +3 more
  • (no location specified)
Jun 9, 2023

Non-hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma Trial in United States (IMMU-114)

Terminated
  • Non-hodgkin's Lymphoma
  • +5 more
  • Newark, Delaware
  • +4 more
Aug 12, 2021

Cervical Cancer Trial (Sacituzumab Govitecan)

Not yet recruiting
  • Cervical Cancer
  • Sacituzumab Govitecan
  • (no location specified)
Apr 18, 2023

Ovarian Carcinoma Trial in New Haven (Sacituzumab govitecan)

Not yet recruiting
  • Ovarian Carcinoma
  • Sacituzumab govitecan
  • New Haven, Connecticut
    Smilow Cancer Hospital at Yale New Haven
Aug 31, 2023

Lymphoma Trial in Houston (PCV20)

Not yet recruiting
  • Lymphoma
  • PCV20
  • Houston, Texas
    M D Anderson Cancer Center
Sep 20, 2023

Thyroid Eye Disease Trial (Satralizumab, Placebo)

Not yet recruiting
  • Thyroid Eye Disease
  • (no location specified)
Oct 25, 2023

Relapsing Multiple Sclerosis Trial in Fort Collins, Farmington (Ublituximab)

Recruiting
  • Relapsing Multiple Sclerosis
  • Ublituximab
  • Fort Collins, Colorado
  • +1 more
May 26, 2023

WOE of Anti-CD20 Therapies

Not yet recruiting
  • Multiple Sclerosis
  • (no location specified)
Oct 31, 2023

Thyroid Eye Disease Trial (Satralizumab, Placebo)

Not yet recruiting
  • Thyroid Eye Disease
  • (no location specified)
Aug 4, 2023

NSCLC Stage IV Trial (HLX26, Serplulimab, Pemetrexed)

Not yet recruiting
  • NSCLC Stage IV
  • (no location specified)
Mar 15, 2023

Nasopharyngeal Carcinoma by AJCC V8 Stage Trial in Guanzhou (HLX07, HLX10, )

Not yet recruiting
  • Nasopharyngeal Carcinoma by AJCC V8 Stage
  • Guanzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 23, 2022